$4.49
-0.13 (-2.81%)
Open$4.62
Previous Close$4.62
Day High$4.62
Day Low$4.28
52W High$14.71
52W Low$1.50
Volume—
Avg Volume65.4K
Market Cap7.51M
P/E Ratio—
EPS$-17.72
SectorBiotechnology
Analyst Ratings
Strong Buy
8 analysts
Price Target
+370.6% upside
Current
$4.49
$4.49
Target
$21.13
$21.13
$13.63
$21.13 avg
$23.51
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 2.00M | 1.99M | 1.61M |
| Net Income | -74,230 | -69,635 | -62,110 |
| Profit Margin | -3.7% | -3.5% | -3.9% |
| EBITDA | -116,342 | -139,946 | -107,891 |
| Free Cash Flow | -67,743 | -57,560 | -72,298 |
| Rev Growth | +11.8% | +24.3% | -3.3% |
| Debt/Equity | 0.69 | 0.66 | 0.82 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $214.87 | -1.20% | 166.6 | 397.77B |
| AMGN | Amgen Inc | $354.05 | +0.63% | 24.7 | 190.40B |
| GILD | Gilead Sciences Inc | $140.73 | +0.98% | 19.6 | 166.66B |
| VRTX | Vertex Pharmaceuticals Inc | $449.71 | +0.71% | 29.1 | 114.87B |
| REGN | Regeneron Pharmaceuticals | $776.21 | +0.46% | 17.9 | 80.50B |
| ALNY | Alnylam Pharmaceuticals Inc | $330.87 | +4.68% | 139.7 | 43.84B |